

JUNE 2021 VOL 2 NO 1



Pharmaceutical Pharmaceutical Echnology



www.jpharm.tech



"Nothing exists until it is measured."

Niels Bohr



JPharmTech Info

Current Issue

JUNE 2021 Volume 2 No 1

e-ISSN: 2717-7904

Website

https://dergipark.org.tr/en/pub/jpharmtech https://www.jpharm.tech

Abbreviation

J Pharm Technol

Contact

editor@jpharm.tech info@jpharm.tech

Publisher

Mustafa Sinan KAYNAK



Journal of Pharmaceutical Technology "**JPharmTech**" is an online peer-reviewed journal following the guidelines provided by the International Committee of Medical Journal Editors (ICMJE), and Committee on Publication Ethics (COPE). All published articles in the **JPharmTech** will be assigned with a unique Digital Objective Identifier (DOI) provided by CrossRef and archived by the LOCKSS system, which guarantees long-term digital preservation of the paper.

JPharmTech is an open-access journal. It provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. The manuscripts submitted to the **JPharmTech** are double-blind peer-reviewed, and the review process is completed in approximately 30 days. According to the reviewers' comments, the submitted papers are accepted or rejected. Submitted manuscripts must not have been previously published elsewhere and not currently be under review by another journal.

Processing and publication are free of charge. **JPharmTech** publishes three issues per year (April, August, and December) and accepts research articles and review articles on all aspects of pharmaceutical technology. Corresponding authors should submit their manuscripts through the online submission system of Dergipark. **JPharmTech** is licensed under a Creative Commons Attribution 4.0 International License.





JPharmTech

Editorial Board

(alphabetical order)

Editor in Chief

Müzeyyen DEMİREL Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Associate Editors

Murat Sami BERKMAN Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Mustafa Sinan KAYNAK Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Editorial & Advisory Board Members

Yeşim AKTAŞ Department of Pharmaceutical Technology, Faculty of Pharmacy, Erciyes University, Kayseri, Turkey

Ebru BAŞARAN Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Murat Sami BERKMAN Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Gülay BÜYÜKKÖROĞLU Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Müzeyyen DEMİREL Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Esra DEMİRTÜRK Department of Pharmaceutical Technology, Faculty of Pharmacy, Çukurova University, Adana, Turkey

Hakan EROĞLU Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey

Umay Merve GÜVEN Department of Pharmaceutical Technology, Faculty of Pharmacy, Çukurova University, Adana, Turkey

Mustafa Sinan KAYNAK Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Ahmet Alper ÖZTÜRK Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Behiye ŞENEL Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Timuçin UĞURLU Department of Pharmaceutical Technology, Faculty of Pharmacy, Marmara University, Istanbul, Turkey

Neslihan ÜSTÜNDAĞ OKUR Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Health Sciences, İstanbul, Turkey

Roderick B WALKER Pharmaceutics Division, Faculty of Pharmacy, Rhodes University, Grahamstown, South Africa

Evrim YENİLMEZ Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Gülsel YURTDAŞ KIRIMLIOĞLU Department of Pharmaceutical Technology, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey



JPharmTech Contents

JUNE 2021 Volume 2 No 1

Research Articles

Preliminary study for the development of potent hydrogels for local drug delivery applications Özcan Bülbül E, Siafaka PI, Mutlu G, Üstündağ Okur N *J Pharm Technol*. (2021); 2(1): 65-71 https://doi.org/10.37662/jpt.2021.9

Indexing and Abstracting

JPharmTech is currently indexed in;

Asos Index Eurasian Scientific Journal Index Google Scholar Scientific Indexing Services Research Bible





JPharmTech Editor's Note



Dear Pharmaceutical Technology Researchers,

We are excited to be with you in this new issue of **JPharmTech**. The purpose of our journal is to inform the all pharmaceutical scientists about all latest and important research on drug development. **JPharmTech** will publish papers that focus on the research, development and evaluation of pharmaceutical delivery systems. The journal includes topics such as preformulation, drug delivery systems and targeting, formulation design, preparation, *in vitro* and *in vivo* characterization, pharmacokinetics, pharmacodynamics, biopharmaceutics and more.

JPharmTech is an online peer-reviewed journal following the guidelines provided by International Committee of Medical Journal Editors (ICMJE) and Committee on Publication Ethics (COPE). **JPharmTech** will be published every four months and three issues per year. Journal accepts original research and review articles on all aspects of pharmaceutical technology. Corresponding authors should submit their manuscripts through the online submission system of Dergipark (www.jpharm.tech). Processing and publication are free of charge. All published articles in the **JPharmTech** will be assigned with unique Digital Objective Identifier (DOI) provided by CrossRef; indexed in Google Scholar, Scientific Indexing Services (SIS), Eurasian Scientific Journal Index, Research Bible and ASOS index.

I want to thank you to the all of my friends who studied for those processes that are mentioned above. By the valuable contribution of our friends in the publishing team, this was a successful start for our journal.

Our main goals are having a strong international editor and referee team, to increase the recognition and index number of the **JPharmTech** and to be one of the most cited journals. That's why, your contribution and support to our journal with your papers and refereeing, are really important and valuable for us.

Thank you in advance & Best regards,

Müzeyyen Demirel

Journal of Pharmaceutical Technology Editor in Chief



JPharmTech Guide for Authors

Authors should carefully read the following explanations and follow the **JPharmTech** rules.

Submission

The publication language of the **JPharmTech** is English. Please perform spell and grammar check of the article. Authors, for whose native language is not English, are strongly encouraged to have their manuscript carefully edited prior to submission. Before submitting, all contributors must agree and sign the Copyright Form. The following three documents must be uploaded for article submission.

- Copyright Form (form available online)
- Title Page Document (*template available* online)
- Manuscript Body Document (*template available* online)

All articles should be submitted online, unless otherwise instructed by the editors. Our online submission system guides you stepwise through the process of entering your article details and uploading your files. After the submission, the manuscripts will be edited according to the **JPharmTech** submission format and authors may be requested for some corrections or for addition of any missing information. There is no submission or page charges for the **JPharmTech**.

The main article types are as follows:

Research Articles

The **JPharmTech** considers all original research articles provided that the work reports scientifically sound experiments and provides a substantial amount of new information. The main text of original articles should be structured according to the "Article Structure" title given below.

Review Articles

Review articles provide concise and precise updates on the latest progress made in a given area of research. Reviews prepared by authors who have extensive knowledge on a particular field and whose scientific background has been translated into a high volume of publications with a high citation potential are welcomed.

General Rules

The main text should be 1000-7000 words long (not including abstract, keywords and references). All headings must be numbered consecutively and hierarchically. Please avoid using more than three levels of headings. The proposed location of figures and tables must be indicated in the main text. Within the article, avoid the use of footnotes and endnotes. Prefer to use the active voice throughout, not the passive, while explaining the study performed.

Symbols, abbreviations and conventions in papers must follow the recommended SI Units. A single space must be placed between the number and the unit. Abbreviations must be defined in brackets after their first mention in the text in accordance with internationally agreed rules.

Mathematical symbols and formulae must be typed in Microsoft Word and any other application or program must not be used. If necessary, they should also be numbered consecutively and uploaded separately in jpeg format. Equation numbers must be in parentheses and numbered consecutively. All equation numbers must appear on the right-hand side of the equation and must be referred to within the text.

Please use a decimal point rather than a comma in numbers (i.e. 3.142 not 3,142). Write numbers less than 1 as 0.54 not as .54. Report summary rather than raw data. Do not use "average". Instead, specify which type of "average" you report (mean, median, mode, etc.). Present means and standard deviation/standard error in the format $X \pm SD/SE$ unit (i.e., mean body weight = 6.38 ± SD 1.29 kg). Present ranges as "range: 15-29".

Figures and Tables

The total number of tables and figures must not exceed 10. If your figure is created in a Microsoft Office application then please upload the original document. Submit each figure as a separate file. Figures must have a minimum 300 dpi resolution. Figures should be properly sized and cropped according to the **JPharmTech** page format or column size.



Please do not supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors. Ensure that each figure has a caption with a figure number.

Submit tables as editable text in Microsoft Word, not as images. Table headings should be given above the table and written in sentence case. Please avoid using vertical borders. Ensure that each table has a caption with a table number.

Style

Check out the **JPharmTech** manuscript template for detailed information. All manuscripts must be uploaded in editable Microsoft Word format with separately added figures/table files. Do not mix different font styles in text and figures/tables.

Use Times New Roman Font with 11-point font size in text and 10 point in tables. Use 1.5 line spacing, do not leave extra space between paragraphs. Preferably use left and right justified text, do not use any right or left identation. Use clear black text on a white background. All pages must be numbered consecutively.

Plagiarism

All submissions are screened by a similarity detection software (iThenticate by CrossCheck) at any point during the peer-review or production process. Even if you are the author of the phrases or sentences, the text should not have unacceptable similarity with the previously published data.

Article Structure

Research Papers should be organized as follows: Title, Author names and affiliations, Corresponding author information, Abstract, Keywords, Introduction, Materials and methods, Results and Discussion, Conclusion, Author contributions, Acknowledgments (if any), Ethics committee approval (if necessary), Conflict of interest declaration, References. These rules are a bit more flexible in review articles.

Title

A concise and informative title is required. Do not use any abbreviations and formulae in the title of the manuscript. The title of the manuscript must be written in sentence case except for the first word and proper nouns.

Author Names and Affiliations

Clearly indicate the given name(s) and family name(s) of each author. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a superscript number.

Corresponding Author Information

Clearly indicate who will handle correspondence at all stages of publication. Corresponding Author details including name, complete address, phone, fax, and e-mail must be added. The first author will be taken as the corresponding author when no corresponding author is assigned.

Abstract

A concise and factual abstract of maximum 250 words is required. The abstract should state the purpose of the research, the experimental studies, the principal results and the major conclusions. Graphical or structured abstracts are not preferred for the **JPharmTech**. Do not cite any references and do not use any abbreviations in the abstract.

Keywords

Immediately after the abstract, maximum 5 keywords should be stated in alphabetical order. Keywords must be carefully selected to facilitate the readers' search. The keywords should be listed in full without abbreviations.

Introduction

The introduction section of the articles (particularly research articles) should include the following topics;

- establish current knowledge of the field,
- summarize previous research, providing the wider context and background and the importance of the current study,
- set the stage for the present research, indicating gaps in knowledge and presenting the research question,
- introduce present research, stating its purpose and outlining its design.



Material and Methods

The Methods should describe clearly how you carried out your study. Provide sufficient details like study design and data collection to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference.

Results and Discussion

A combined Results and Discussion section is often appropriate; but optionally can be written separately. Provide a concise and precise description of the all experimental data, their interpretation as well as the experimental conclusions that can be drawn. Discussion should explore the significance of the results of the work, not repeat them. The P values and/or the specific statistical tests performed for each experiment should be included to the results and discussion section in the appropriate figure legend or main text. Results should include the name of the statistical test, followed by a colon, the test statistic and its value, degrees of freedom or sample size (depending on which is most appropriate for that test), and the P value, with indication if it is one-or two-tailed (unless you address this issue in the methods).

Conclusion

The conclusion section of the articles (particularly research articles) should include the following topics;

- principles, relationships, and generalizations inferred from the results (but not a repetition of the results),
- any exceptions to or problems with those principles, relationships, and generalizations, as indicated by the results agreements or disagreements with previously published work,
- theoretical implications and possible practical applications of the work,
- conclusions drawn (especially regarding significance).

Author Contributions

Articles with several authors, a short paragraph specifying their individual contributions must be provided. The following statements should be used:

Concept, Design, Supervision, Materials, Data Collection and/or Processing, Analysis and/or Interpretation, Literature Search, Writing, Critical Reviews. Initials of the contributing authors (i.e. AA, BB) should be given after these specified titles and all of them must be filled.

Acknowledgments

Acknowledgments should include sources of support, grants, disclaimers, names of those who contributed but are not authors, etc. The names of funding organizations should be written in full. If no funding or help has been provided for the research, please include the "None" statement.

Conflict of Interest Declaration

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence their work. If no conflict exists, the authors should include the "The authors declare no conflict of interest." statement under this section.

Ethics Committee Approval

When reporting experiments conducted with humans indicate that the procedures were in accordance with ethical standards set forth by the committee that oversees human experimentation. Approval of research protocols by the relevant ethics committee, in accordance with international agreements.

Helsinki Declaration of 1964, revised 2013 available at

https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/

Guide for the Care and use of Laboratory Animals available at

www.nap.edu/catalog/5140.html

is required for all experimental, clinical, and drug studies. Patient names, initials, and hospital identification numbers should not be used. Manuscripts reporting the results of experimental investigations conducted with humans must state that the study protocol received institutional review board approval and that the participants provided informed consent.



References

Citation in text must be numbered as [1] or [1-5]. Please ensure that every reference cited in the text is also present in the reference list. References should be accurate and numbered sequentially [in square brackets] in the text and listed in the same numerical order in the reference section with the DOI link. All authors must be cited and there should be no use of the phrase et al. The abbreviations of the journal names should be used. No references sould be given for the abstract section. Date of access should be provided for online citations. Furthermore, the references can easily be edited with the **JPharmTech** EndNote Style.

See below few examples of references listed in the **JPharmTech** style.

Journal

- Ates M, Kaynak MS, Sahin S. Effect of permeability enhancers on paracellular permeability of acyclovir. *J Pharm Pharma-col.* (2016); 68(6): 781-790. https://doi.org//10.1111/jphp.12551
- [2] Kaynak MS, Celebier M, Akgeyik E, Sahin S, Altınoz S. Application of HPLC to investigate the physicochemical properties and intestinal permeability of ketoprofen. *Curr Pharm Anal.* (2017); 13(1): 72-79. https://doi.org/10.2174/1573412912666160422151409
- [3] Başaran E, Yenilmez E, Berkman MS, Büyükköroğlu G, Yazan Y. Chitosan nanoparticles for ocular delivery of cyclosporine A. J Microencapsul. (2014); 31(1): 49-57. https://doi.org/10.3109/02652048.2013.805839

Book

- [4] Fotaki N, Klein S. *In vitro* drug release testing of special dosage forms. New Jersey: John Wiley & Sons; (2019). ISBN:1118341473
- [5] Wilson CG, Crowley PJ. Controlled release in oral drug delivery. New York: Springer; (2011). ISBN:1461410045

Book Chapter

- [6] Clayton NS, Emery NJ. What do jays know about other minds and other times? In: Berthoz A, Christen Y, editors. Neurobiology of "Umwelt". Berlin: Springer; (2009). p. 109-123. ISBN:3540858962
- [7] Pepperberg IM. Symbolic communication in the Grey parrot. In: Vonk J, Shackelford T, editors. The Oxford handbook of comparative evolutionary psychology. New York: Oxford University Press; (2012). p. 297-319. ISBN:0199738181

Conference Paper

[8] Yurtdaş Kırımlığlu G, Özer S. "Formulation and *in vitro* characterization studies of levofloxacin hemihydrate incorporated PLGA based nanoparticles." Poster. 2nd International Gazi Pharma Symposium Series, Ankara, October 11-13, 2017. p. 93.

Patent

[9] Wong HL, Narvekar M, Xue HY, inventors; Temple University, assignee. Nanospheres for therapeutic agent delivery. United States patent no 9724304. (2017).

Thesis

- [10] Arora HC. Doxorubicin-nanocarriers enhance doxorubicin uptake and clathrin-mediated endocytosis in drug-resistant ovarian cancer cells [Ph.D.]. Illinois: Northwestern University; (2012).
- [11] Finn NA. Role of redox systems in doxorubicin metabolism and doxorubicin-mediated cell signaling: a computational analysis [Ph.D.]. Atlanta: Georgia Institute of Technology; (2011).

Website

[12] Secretariat E. The agreement on the conservation of populations of European bats. (2004). EUROBATS. Retrieved April 1 2020 from https://www.eurobats.org/index.htm

Please check that this *guide* is up to date.

JPharmTech



www.jpharm.tech